MDGN Share Price

Open 5.08 Change Price %
High 5.14 1 Day -0.06 -1.19
Low 4.96 1 Week -0.84 -14.38
Close 5.00 1 Month 0.54 12.11
Volume 148934 1 Year -1.56 -23.78
52 Week High 6.75
52 Week Low 3.09
MDGN Important Levels
Resistance 2 5.17
Resistance 1 5.10
Pivot 5.03
Support 1 4.90
Support 2 4.83
AMEX USA Most Active Stocks
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
CVM 0.11 -38.89%
CVM 0.11 -38.89%
PLX 0.31 -44.64%
PLX 0.31 -44.64%
RBY 0.03 -70.00%
NAK 1.45 21.85%
NAK 1.45 21.85%
More..
AMEX USA Top Gainers Stocks
GGR 0.02 100.00%
CMFO 0.12 100.00%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
MBA 0.20 25.00%
MBA 0.20 25.00%
MBA 0.20 25.00%
IG 7.68 22.49%
More..
AMEX USA Top Losers Stocks
RBY 0.03 -70.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
RVP 1.30 -46.94%
PLX 0.31 -44.64%
PLX 0.31 -44.64%
CVM 0.11 -38.89%
CVM 0.11 -38.89%
QBC 0.20 -33.33%
More..

Medgenics, Inc. (AMEX: MDGN)

MDGN Technical Analysis 3
As on 2nd Dec 2016 MDGN Share Price closed @ 5.00 and we RECOMMEND Sell for LONG-TERM with Stoploss of 5.07 & Sell for SHORT-TERM with Stoploss of 5.25 we also expect STOCK to react on Following IMPORTANT LEVELS.
MDGN Target for December
1st Target up-side 6.2
2nd Target up-side 6.95
3rd Target up-side 7.69
1st Target down-side 4.08
2nd Target down-side 3.33
3rd Target down-side 2.59
MDGN Other Details
Segment EQ
Market Capital 109150520.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.medgenics.com
MDGN Address
MDGN
435 Devon Park Drive
Building 700
Wayne, PA 19087
United States
Phone: 610-254-4201
Interactive Technical Analysis Chart Medgenics, Inc. ( MDGN AMEX USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Medgenics, Inc.
MDGN Business Profile
Medgenics, Inc., a medical technology and therapeutics company, is engaged in the research and development of products in the field of biotechnology and associated medical equipment in the United States. The company develops and commercializes Biopump platform technology that converts a piece of the patient’s own dermal skin tissue into a protein- and/or peptide-producing ‘Biopump’ to produce and deliver therapeutic proteins and/or peptides, and—when implanted under the patient’s skin—has the potential to deliver various months of protein/peptide therapy. Its product candidates include EPODURE Biopump, which is in Phase I/II clinical trials for the treatment of anemia in CKD and renal failure; and HEMODURE Biopump, which is under pre-clinical studies and produces Factor VIII for the treatment of patients with hemophilia. The company also develops INFRADURE Biopump that produces interferon-alpha for the treatment of patients with hepatitis C. Medgenics, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.